Opicapone Inhibitor

Name: Opicapone Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5755308
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755308

Opicapone reduces the ATP content of the cells (IC50: 98 uM). Opicapone is an effective third-generation catechol-O-methyltransferase inhibitor for the research of Parkinson's disease and motor fluctuations. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Opicapone, Inhibitor

Full Product Name

Opicapone

Product Synonym Names

BIA 9-1067

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

413.17

Solubility

DMSO: 100mg/mL (242.03mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C15H10Cl2N4O6

SMILES

CC1=[N+]([O-])C(Cl)=C(C2=NOC(C3=CC([N+]([O-])=O)=C(O)C(O)=C3)=N2)C(C)=C1Cl

CAS Number

923287-50-7

Target & IC50

COMT

In Vitro

Opicapone is also the least potent compound in decreasing both the mitochondrial membrane potential and the ATP content in human primary hepatocytes after a 24 hours incubation period. Opicapone inhibits rat peripheral COMT with ED50 values below 1.4mg/kg up to 6 h post-administration. The effect is sustained over the first 8 h and by 24 hours COMT had not returned to control values. Opicapone (a single administration) resulted in increased and sustained plasma L-DOPA levels with a concomitant reduction in 3-OMD from 2 hours up to 24 hour post-administration, while Ro 40-7592 produces significant effects only at 2 hour post-administration. The effects of Opicapone on brain catecholamines after L-DOPA administration are sustained up to 24 hour post-administration [1].

Product Categories/Family for Opicapone, inhibitor

Metabolism; Transferase

Product References and Citations for Opicapone, inhibitor

Bonifacio MJ, et al. Pharmacological profile of Opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol. 2015 Apr;172(7):1739-52.
Bonifacio MJ, et al. Pharmacological profile of Opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol. 2015 Apr;172(7):1739-52.
Ferreira JJ, et al. Opicapone as an adjunct to L-DOPA in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016 Feb;15(2):154-165.
Ferreira JJ, et al. Opicapone as an adjunct to L-DOPA in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016 Feb;15(2):154-165.

Other Notes

Small volumes of Opicapone, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Opicapone purchase

MBS5755308 is an inhibitor targeting Opicapone.